IP : Iksuda Therapeutics - Announces first patient dosed in

IP : Iksuda Therapeutics - Announces first patient dosed in Phase 1 trial of IKS014 in patients with advanced solid tumours that express HER2 -October 23, 2023 at 07:40 am EDT

23 Oct 2023

Study is designed to evaluate the safety and tolerability of increasing dose levels of the antibody drug conjugate, IKS014, to establish a...

Related Keywords

Australia , China , United Kingdom , Iksuda Adcs , Simon Conway Rob Winder , Dave Simpson , Fosun Pharma , , Iksuda Therapeutics , Chief Executive Officer , Financial Media , Markets ,